Press Releases - Archive



Shareholder Tools


 
Press Releases - Archive
Date Title and Summary View
Aug 25, 2009 San Francisco, CA, August 25, 2009 – Achaogen, a clinical stage biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative, broad-spectrum antibiotics, announced today the appointment of John C. Doyle to the newly created position of chief op...
Jun 30, 2009 San Francisco, CA, June 30, 2009 – Achaogen, a clinical stage biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative broad-spectrum antibiotics, announced today that it has been selected as one of the annual FierceBiotech “Fierce 15...
May 16, 2009 SAN FRANCISCO, UNITED STATES and HELSINKI, FINLAND, May 16, 2009 – Achaogen, a clinical stage biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative broad-spectrum antibiotics, announced today the presentation of research on aminoglycosid...
Mar 23, 2009 SAN FRANCISCO, CA, March 23, 2009 – Achaogen, a clinical stage biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative broad-spectrum antibiotics, today announced that J. Kevin Judice, Ph.D., chief executive officer and chief scientific of...
Mar 10, 2009 SAN FRANCISCO, CA, March 10, 2009 – Achaogen, a clinical stage biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative broad-spectrum antibiotics, today announced that J. Kevin Judice, Ph.D., chief executive officer and chief scientific of...
Mar 3, 2009 SAN FRANCISCO, CA, March 3, 2009 – Achaogen, a clinical stage biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative broad-spectrum antibiotics, today announced that it has been awarded a contract worth up to $26.6 million over five ye...
Feb 3, 2009 SAN FRANCISCO, CA, February 3, 2009 – Achaogen, an emerging biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative broad-spectrum antibiotics, today announced that it has initiated its first Phase 1 clinical trial. This trial is designed ...
Jan 8, 2009 SAN FRANCISCO, CA, January 8, 2009 – Achaogen, an emerging biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative broad-spectrum antibiotics, today announced that it has received a £4.1 million Seeding Drug Discovery award from ...
Dec 17, 2008 SAN FRANCISCO, CA, December 17, 2008 – Achaogen, an emerging biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative broad-spectrum antibiotics, today announced the appointments of Thomas B. King, President and Chief Executive Officer of A...
Oct 24, 2006 SOUTH SAN FRANCISCO, CA — Achaogen, Inc., a developer of novel antibacterial compounds, has executed a four-year contract with the Defense Threat Reduction Agency (DTRA), an agency of the United States Department of Defense, worth up to $24.7 million dollars for the development of therapies to treat anthrax and other bio...
Page: FirstPrevious ...
12
NextLast
= add release to Briefcase